Skip to content
Back to explorer
Printable monograph

IL-3 immunotoxin

Tagraxofusp

Elzonris · Tagrax

IL-3 immunotoxin · approved 2018 · 7 citations · FAERS AKI reporting ROR 4.37 (95% CI 2.90–6.58, 24 AKI reports)

Up to date· through 2026
Fairly sourced6/9 · 6 signals
  • Met: 7 citations
  • Not met: 12+ references
  • Not met: Accrued over 10+ years (span: 6y)
  • Met: Beyond single case reports
  • Met: High-impact journal
  • Met: Landmark reference
  • Met: Current through 2026
  • Met: Real-world FAERS signal

Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.

A CD123-directed diphtheria-toxin fusion whose capillary leak can collapse the circulation and the kidneys.

ModerateIL-3 / CD123-directed immunotoxin
Blastic plasmacytoid dendritic cell neoplasm (BPDCN)

Kidney summary

Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.

Renal dosing
Not in the atlas's table of label-specified renal dose changes; the Dosing section has the full entry.
Hemodialysis
Not removed by hemodialysis
Large fusion protein cleared by proteolysis and not dialyzable; hemodialysis or CRRT supports AKI/volume overload rather than drug removal.
The atlas summary. Full prose in the Dialyzability section.
FDA boxed warning
Yes
Label: Elzonris, Dec 2024. Not necessarily about the kidney. FDA label section.
§01

Signature kidney injury

Capillary leak syndrome (CLS) is a boxed-warning toxicity occurring in ~19-21% of treated patients in the registrational trial (mostly grade 2; grade >=3 in ~4% — 2% grade 3 plus 2% grade 4 — with two deaths); the resulting hypotension, hypoalbuminemia, and fluid shifts can precipitate prerenal AKI and, with prolonged hypoperfusion, ischemic ATN. Renal-specific AKI incidence is not separately quantified.Source: Pemmaraju et al., J Clin Oncol 2022

Onset & rechallenge

Time to injuryAcute (~1–7 days)

Usually during the first cycle, often within days of the first doses.

Distilled from: “Typically during the first treatment cycle, often within days of the first doses; recurrence in later cycles is uncommon with proactive monitoring.”

RechallengeOften tolerated

Recurrence in later cycles is uncommon with proactive monitoring.

§02

Renal toxicities, ranked

This agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.

  1. Capillary leak syndrome in 19% of patients in the pivotal BPDCN trial (fatal in one patient per dose subgroup); CLS drives intravascular volume depletion / prerenal physiology

  2. Acute Tubular NecrosisSecondaryqualitative — no citable incidence

    Direct death of tubular epithelial cells — the dose-limiting lesion of the platinums and zoledronate.

§03

Kidney injury

Mechanism of kidney injury

Endothelial injury from the diphtheria-toxin immunotoxin (CD123 is also expressed on endothelium) produces a systemic capillary-leak state: intravascular fluid and albumin extravasate into the interstitium, causing hypoalbuminemia, edema, weight gain, and hypotension. The fall in effective circulating volume drives prerenal azotemia and, when severe or prolonged, ischemic acute tubular necrosis.

Clinical presentation

Weight gain, peripheral and pulmonary edema, hypoalbuminemia (often <3.0 g/dL), hypotension, and rising creatinine, usually in cycle 1. Falling serum albumin and rising weight are the earliest CLS signals; severe cases progress to shock and pulmonary edema.

Management

Treat CLS aggressively: corticosteroids, IV albumin to support oncotic pressure, judicious fluid management, and interruption of tagraxofusp. Support blood pressure and renal perfusion (vasopressors if needed). Most AKI is prerenal and improves with CLS resolution; established ATN requires standard supportive care and occasionally renal replacement therapy.Lesion-level management framework

Risk factors

  • Low baseline serum albumin (<3.2 g/dL)
  • Pre-existing cardiac or volume-overload states
  • First cycle of therapy
  • Pre-existing low platelet count / bleeding risk amplifying hemodynamic instability

Prevention

  • Require serum albumin >= 3.2 g/dL before the first dose and before each subsequent dose
  • Premedicate (corticosteroids, antihistamines, antipyretics) and give prompt corticosteroids and albumin at the first CLS signs; hold dosing per protocol
Anticancer mechanism· how it treats cancer

Recombinant fusion of interleukin-3 (IL-3) and truncated diphtheria toxin that binds the IL-3 receptor alpha chain (CD123) overexpressed on malignant cells, internalizes, and the diphtheria-toxin payload ADP-ribosylates elongation factor 2 to halt protein synthesis and trigger apoptosis. First approved therapy for blastic plasmacytoid dendritic cell neoplasm (BPDCN).

Note · Capillary-leak syndrome carries a boxed warning; renal injury is a downstream consequence of endothelial leak and hemodynamic collapse rather than direct tubular toxicity.
§04

Clinical depth

Renal dose adjustment

No established renal dose adjustment (clearance is proteolytic, not renal). Dosing decisions hinge on albumin, weight, and CLS status rather than eGFR.

Dialyzability & ESKD dosing

Large fusion protein cleared by proteolysis; not dialyzable. Hemodialysis/CRRT is used to support AKI/volume overload, not to remove the drug.

Differential diagnosis

Tagraxofusp CLS-driven prerenal AKI/ATN (hypoalbuminemia, weight gain, edema in cycle 1) vs sepsis/neutropenic shock vs cardiogenic edema vs tumor-related fluid overload. Hypoalbuminemia with weight gain and hemoconcentration points to CLS.

Monitoring

  • Serum albumin before each dose (hold if <3.2 g/dL)
  • Daily weight and blood pressure during cycle 1
  • Edema, oxygen saturation, and signs of pulmonary edema
  • Daily serum albumin during cycle 1 inpatient observation

Key trials & series

  • Pemmaraju phase 1/2 pivotal BPDCN trial (NEJM 2019) and JCO 2022 long-term follow-up
  • Pemmaraju & Konopleva Blood Adv 2020 approval review

Clinical pearls

  • Albumin is the vital sign for tagraxofusp - do not dose if <3.2 g/dL.
  • CLS clusters in cycle 1; intensive monitoring then prevents most severe events.
  • The AKI is a hemodynamic consequence of capillary leak, not a direct tubular toxin - fix the circulation and the kidney follows.
Where it strikes· nephron segments & injury signatures

Nephron segments

Vasculature / Endothelium

Glomerular & peritubular capillaries

Proximal Tubule

Bulk reabsorption + drug uptake (OCT2, OATs)

§05

References

6 primary references — trials, cohorts, mechanism, and reviews. Single-patient case reports are listed separately below, graded by strength. Citation metadata via PubMed / NLM.

Evidence accrual

6 references · 2020–2025 · 3 since 2023
202020: 1 citation2021: 1 citation2022: 1 citation2023: 1 citation2025: 2 citations20202025

Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.

  1. 1.LandmarkLong-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm.Pemmaraju N et al. · J Clin Oncol · 2022 · PMID 35820082Largest prospective BPDCN trial with long-term follow-up; quantifies CLS at 21% (grade >=3 7%), the driver of hemodynamic/renal compromise.
  2. 2.Optimizing capillary leak syndrome prevention and management in patients receiving tagraxofusp for blastic plasmacytoid dendritic cell neoplasm.Lane AA et al. · Leuk Lymphoma · 2025 · PMID 41134616Focused guidance on preventing and managing tagraxofusp CLS: albumin thresholds, monitoring, and early intervention.
  3. 3.Approval of tagraxofusp-erzs for blastic plasmacytoid dendritic cell neoplasm.Pemmaraju N et al. · Blood Adv · 2020 · PMID 32841341Drug-development and approval review detailing mechanism and the black-box capillary leak syndrome.
  4. 4.Blastic Plasmacytoid Dendritic Cell Neoplasm.Jain A et al. · J Natl Compr Canc Netw · 2023 · PMID 37156483Disease and treatment review emphasizing CLS as a key adverse effect requiring close monitoring.
  5. 5.Reversible Myocardial Edema Secondary to Tagraxofusp-Induced Capillary Leak Syndrome.Mouhayar EN et al. · JACC CardioOncol · 2021 · PMID 34988487Illustrates the systemic fluid shifts and end-organ edema produced by tagraxofusp capillary leak.
  6. 6.Efficacy of first-line tagraxofusp in blastic plasmacytoid dendritic cell neoplasm with prior or concomitant hematologic malignancy: subgroup analysis of a pivotal trial.Pemmaraju N et al. · Leuk Lymphoma · 2025 · PMID 40067964Pivotal-trial subgroup data reinforcing the efficacy/safety profile, including monitored capillary-leak risk.
Case reports — ranked by strength· 1

Single-patient and small-series reports, graded by evidentiary strength — A Strong (biopsy-proven plus a series and/or positive rechallenge), B Moderate, and C Limited (a single clinically-diagnosed case). Strongest first. Grades are inferred automatically from each report's abstract and journal — a heuristic ranking aid, not a formal quality appraisal.

FDA label — boxed warning & renal dosing· boxed warning · 1 kidney table row

Quoted verbatim from this agent's current FDA label (Dec 2024) — not paraphrased or interpreted. Full label on DailyMed .

Boxed warning

WARNING: CAPILLARY LEAK SYNDROME Capillary Leak Syndrome (CLS) which may be life-threatening or fatal, can occur in patients receiving ELZONRIS. Monitor for signs and symptoms of CLS and take actions as recommended [see Warnings and Precautions ( 5.1 )] . WARNING: CAPILLARY LEAK SYNDROME See full prescribing information for complete boxed warning. Capillary Leak Syndrome (CLS), which may be life-threatening or fatal if not properly managed, can occur in patients receiving ELZONRIS. ( 5.1 )

Kidney rows of the label's dosage tables

From the Elzonris label (Dec 2024) · DailyMed

The rows that name proteinuria, nephrotic syndrome, creatinine, creatinine clearance, renal or nephritis together with a withhold, reduce, resume or discontinue instruction, reproduced cell for cell. A merged cell is written out on each row it covers. The tables' footnotes are not reproduced, and they can hold the conditions for resuming: read the full table on DailyMed. Educational only, not medical advice.

Table 1. Recommended ELZONRIS Dosage Modifications
Serum creatinineSerum creatinine > 1.8 mg/dL (159 micromol/L) or creatinine clearance < 60 mL/minuteWithhold ELZONRIS until serum creatinine resolves to ≤ 1.8 mg/dL (159 micromol/L) or creatinine clearance ≥ 60 mL/minute.

What gets reported — FAERS

Everything below is FAERS — adverse events someone chose to report, about 538 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.

  • Reporting odds ratio (ROR) — is kidney injury named in this agent's reports more often than in every other drug's? Above 1 means yes, disproportionately.
  • Outcomes — a share of this agent's own reports, not of patients: how many were filed as involving a death or a hospitalization. Not a case-fatality rate.
FAERS outcomes & reporting trend· 29.9% of reports w/ death · 25.1% w/ hospitalization
29.9%

Reported with a death outcome

161 of 538 reports

25.1%

Reported with hospitalization

135 of 538 reports

Reports per year

  • 2015: 0 reports
  • 2016: 0 reports
  • 2017: 0 reports
  • 2018: 0 reports
  • 2019: 58 reports
  • 2020: 60 reports
  • 2021: 75 reports
  • 2022: 72 reports
  • 2023: 87 reports
  • 2024: 69 reports
  • 2025: 63 reports
  • 2026: 54 reports

Reports received per year, 2015–2026 · most recent year is partial.

FAERS adverse-event signal — all organ systems· 10 systems · 538 reports

Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.

Disproportionality (acute kidney injury):ROR 4.3795% CI 2.90–6.58· 24 AKI reports· IC025 1.35·AKI is reported disproportionately more often than for other drugs (CI entirely above 1) — a hypothesis-generating signal, not proof of causation.
Renal & urinary
Acute Kidney Injury24
Hepatobiliary
Transaminases Increased22Aspartate Aminotransferase Increased19Liver Function Test Increased19Alanine Aminotransferase Increased17Hepatic Enzyme Increased17
General / constitutional
Pyrexia47Weight Increased28Fatigue16
Metabolic & electrolyte
Tumour Lysis Syndrome27Hypoalbuminaemia25
Blood & lymphatic
Thrombocytopenia35Platelet Count Decreased15
Immune / infection
Sepsis23Pneumonia17
Vascular
Hypotension22
Respiratory
Dyspnoea16
Cardiac
Atrial Fibrillation13
Psychiatric
Confusional State13
Guidelines & consensus· 13

Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.

General onco-nephrology references

ADQIThe nephrotoxic effects of anti-cancer therapies: consensus report of the 34th Acute Disease Quality Initiative workgroupNat Rev Nephrol 2026 · PMID 41361704Provides expert-based statements (modified Delphi) on preventing and managing cisplatin/platinum-associated AKI, including isotonic IV hydration, attention to volume status and concomitant nephrotoxins, and incorporates evidence that IV magnesium supplementation may reduce cisplatin-associated AKI; emphasizes risk stratification and standardized AKI definitions.SIRMSIRM-SIN-AIOM: appropriateness criteria for evaluation and prevention of renal damage in the patient undergoing contrast medium examinations-consensus statements from Italian College of Radiology (SIRM), Italian College of Nephrology (SIN) and Italian Association of Medical Oncology (AIOM)Radiol Med 2022 · PMID 35303246Recommends eGFR-based renal risk assessment and pre/post-contrast isotonic saline or sodium bicarbonate hydration; advises maintaining a 5-7 day interval between iodinated contrast administration and cisplatin in cancer patients to reduce additive nephrotoxicity.KDIGOKDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancerKidney Int 2020 · PMID 33126977Identifies platinum compounds (especially cisplatin) as leading cytotoxic causes of acute tubular injury, AKI, and electrolyte/magnesium wasting; calls for interdisciplinary onco-nephrology care, accurate GFR estimation, and individualized drug dosing in patients with reduced kidney function.KDIGOKDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantationKidney Int 2020 · PMID 33276867Addresses chemotherapy-associated AKI/CKD in hematologic cancer, GFR estimation and chemotherapy dosing in patients with reduced kidney function, and management priorities and research gaps for onco-nephrology care.ADDIKDIntegrating International Consensus Guidelines for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) into everyday practiceEClinicalMedicine 2025 · PMID 40290844Provides GRADE-based, drug-specific dose-adjustment recommendations for anticancer agents in kidney dysfunction (illustrated for methotrexate, cisplatin, carboplatin and nivolumab); the recommendations build on Part 1's standardised CKD-EPI eGFR assessment rather than Cockcroft-Gault creatinine clearance.ADDIKDAligning kidney function assessment in patients with cancer to global practices in internal medicineEClinicalMedicine 2025 · PMID 40290845Three consensus recommendations: assess kidney function by GFR (measured GFR or CKD-EPI eGFR), classify it using KDIGO categories, and use this uniform approach to dose anticancer drugs — moving cancer medicine away from Cockcroft-Gault estimated creatinine clearance.ADDIKDA methodology for determining dosing recommendations for anticancer drugs in patients with reduced kidney functionEClinicalMedicine 2025 · PMID 40290846Establishes that, where RCT evidence is lacking, anticancer drug dosing recommendations in kidney dysfunction should be derived by critically appraising observational literature via GRADE combined with structured international multidisciplinary consensus voting.KDIGODiagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1)Crit Care 2013 · PMID 23394211Defines/stages AKI by serum creatinine and urine output; emphasizes avoiding nephrotoxins, maintaining euvolemia/perfusion, dose-adjusting drugs to kidney function, and monitoring high-risk patients — the framework applied to nephrotoxic anti-cancer agents.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknownsKidney Int 2024 · PMID 38519239Evaluate and risk-stratify CKD, manage to delay progression and its complications, and practise explicit medication management and drug stewardship — the framework the atlas's G1–G5 eGFR banding and every renal dose-adjustment recommendation sit inside. Because the guideline excludes dialysis and transplant recipients by its own statement of scope, its recommendations do not carry to those settings, where this atlas's dialyzability and post-transplant guidance rests on other sources.KDIGOExecutive summary of the KDIGO 2021 Guideline for the Management of Glomerular DiseasesKidney Int 2021 · PMID 34556300Provides the staging/treatment framework for drug-associated glomerular lesions (e.g., bisphosphonate- and interferon-related collapsing FSGS, VEGF-inhibitor podocytopathy/proteinuria), including immunosuppression and supportive RAAS-blockade strategies.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of ANCA-Associated VasculitisKidney Int 2024 · PMID 38388147Updates immunosuppressive induction (rituximab/cyclophosphamide), incorporates avacopan and lower-dose or glucocorticoid-sparing regimens — the management framework for drug- and checkpoint-inhibitor-associated ANCA/pauci-immune glomerulonephritis.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of Lupus NephritisKidney Int 2024 · PMID 38182299Updates first-line lupus nephritis therapy to combination immunosuppression with the addition of belimumab or a calcineurin inhibitor (voclosporin) — informs management of immune-complex/lupus-like glomerulonephritis encountered with immunotherapy.KDIGOExecutive summary of the KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV)Kidney Int 2025 · PMID 40975525Encourages liberal kidney biopsy and stricter proteinuria control (<0.5 g/d, ideally <0.3 g/d) with RAAS blockers, SGLT2 inhibitors, and targeted-release budesonide — the framework for IgA-dominant glomerular lesions, including those triggered by immune-modulating cancer therapy.

Where Tagraxofusp sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.

Position is a 2-D projection (MDS) of each agent's injury signature, nephron target, severity, and class, so two dots can sit close on the page while differing on an axis the projection flattened — the numbered ranking is computed from the full metric, not from the distance you see. Open the full map.
Phenotype-similar agents· the numbered markers on the map above

Tretinoin (ATRA)

Vesanoid · Retinoid (differentiating agent)

Profile

Differentiation syndrome → capillary leak and AKI.

PREATN
Moderate#1 · 100% phenotype match

Sotorasib

Lumakras · KRAS G12C inhibitor

Profile

Newer agent; renal data emerging.

PREATN
Mild#2 · 95% phenotype match

Talquetamab

Talvey · Bispecific (GPRC5D×CD3)

Profile

CRS-related AKI — emerging.

PREATN
Moderate#3 · 89% phenotype match

Teclistamab

Tecvayli · Bispecific (BCMA×CD3)

Profile

CRS-associated AKI in myeloma — emerging signal.

PREATN
Moderate#4 · 89% phenotype match

Tasonermin

Beromun · Recombinant TNF-α (cytokine)

Profile

Isolated-limb-perfusion agent; systemic leakage → SIRS/hypotension → prerenal AKI.

PREATN
Moderate#5 · 88% phenotype match

Arsenic trioxide

Trisenox · Differentiating agent

Profile

Differentiation syndrome; QT prolongation.

PREATNLYTE
Moderate#6 · 84% phenotype match
Compare Tagraxofusp with its nearest agents

Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.